India Cuts Prices Of 463 Anticancers But Loose Ends Remain

Prices of over 400 anticancers have been revised downwards in India by the capping of trade margins, but some healthcare activists say that real benefits for patients could still be elusive. Pharma is also required to maintain production volumes in the new scenario – will it pinch?